The sentinel node procedure in breast cancer: Nuclear medicine as the starting point

Journal of Nuclear Medicine

Volumn 52, Issue 3, 2011, Pages 405-414

  Hindié, Elif ^a   Groheux, David ^a   Brenot Rossi, Isabelle ^b   Rubello, Domenico ^c   Moretti, Jean Luc ^a   Espié, Marc ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Breast cancer; Internal mammary node; Lymphoscintigraphy; Micrometastases; Neoadjuvant chemotherapy; Radiation therapy; Sentinel node biopsy

Indexed keywords

ANTIMONY TECHNETIUM SULFIDE TC 99M; FLUORODEOXYGLUCOSE F 18; ISOSULFAN BLUE; RHENIUM SULFIDE COLLOID TC 99M; TECHNETIUM 99M; TECHNETIUM SULFUR COLLOID TC 99M;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FALSE NEGATIVE RESULT; HIGH RISK PATIENT; HUMAN; INTRADUCTAL CARCINOMA; INTRAOPERATIVE PERIOD; ISOTOPE LABELING; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MASTECTOMY; MICROMETASTASIS; MORBIDITY; POSTOPERATIVE COMPLICATION; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURGICAL DRAINAGE; TUMOR CELL; TUMOR RECURRENCE; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79952787517     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.081711     Document Type: Review

References (71)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-187. (Pubitemid 19032001)
3. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7:122-192.
4. Blamey RW, Hornmark-Stenstam B, Ball G, et al. ONCOPOOL: a European database for 16,944 cases of breast cancer. Eur J Cancer. 2010;46:56-71.
5. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335-339.
6. Bleiweiss IJ. Sentinel lymph nodes in breast cancer after 10 years: rethinking basic principles. Lancet Oncol. 2006;7:686-692. (Pubitemid 44123580)
7. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
8. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in earlystage breast cancer. J Clin Oncol. 2005;23:7703-7720. (Pubitemid 46291835)
9. Hindié E, Groheux D, Espie M, et al. Sentinel node biopsy in breast cancer. Bull Cancer. 2009;96:713-725.
10. Mariani G, Moresco L, Viale G, et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med. 2001;42:1198-1215. (Pubitemid 32717839)
11. Aarsvold JN, Alazraki NP. Update on detection of sentinel lymph nodes in patients with breast cancer. Semin Nucl Med. 2005;35:116-128. (Pubitemid 40568744)
12. Buscombe J, Paganelli G, Burak ZE, et al. Sentinel node in breast cancer procedural guidelines. Eur J Nucl Med Mol Imaging. 2007;34:2154-2159. (Pubitemid 350212147)
13. Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23:4312-4321. (Pubitemid 46209968)
14. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599-609. (Pubitemid 43904843)
15. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595-600.
16. Zavagno G, De Salvo GL, Scalco G, et al. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207-213. (Pubitemid 351156760)
17. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927-933.
18. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106:4-16. (Pubitemid 43033320)
19. Gill G; SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol. 2009;16:266-275.
20. Goyal A, Newcombe RG, Chhabra A, Mansel RE; ALMANAC Trialists Group. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer: results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99:203-208. (Pubitemid 44268268)
21. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymphnode resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881-888. (Pubitemid 47488052)
22. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087-2106. (Pubitemid 41797643)
23. Chakera AH, Hesse B, Burak Z, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging. 2009;36:1713-1742.
24. McMasters KM, Wong SL, Martin RC II, et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg. 2001;233:676-687. (Pubitemid 32378652)
25. Rodier JF, Velten M, Wilt M, et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial. J Clin Oncol. 2007;25:3664-3669. (Pubitemid 47372605)
26. Suami H, Pan WR, Mann GB, Taylor GI. The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study. Ann Surg Oncol. 2008;15:863-871.
27. Anan K, Mitsuyama S, Kuga H, et al. Double mapping with subareolar blue dye and peritumoral green dye injections decreases the false-negative rate of dyeonly sentinel node biopsy for early breast cancer: 2-site injection is more accurate than 1-site injection. Surgery. 2006;139:624-629. (Pubitemid 44269318)
28. Noguchi M, Inokuchi M, Zen Y. Complement of peritumoral and subareolar injection in breast cancer sentinel lymph node biopsy. J Surg Oncol. 2009;100:100-105.
29. Kim SC, Kim DW, Moadel RM, et al. Using the intraoperative hand held probe without lymphoscintigraphy or using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: a review of the literature. World J Surg Oncol. 2005;3:64.
30. van Rijk MC, Tanis PJ, Nieweg OE, et al. Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer. J Surg Oncol. 2006;94:281-286. (Pubitemid 44330850)
31. Johnson MT, Guidroz JA, Smith BJ, et al. A single institutional experience of factors affecting successful identification of sentinel lymph node in breast cancer patients. Surgery. 2009;146:671-676.
32. Brenot-Rossi I, Houvenaeghel G, Jacquemier J, et al. Nonvisualization of axillary sentinel node during lymphoscintigraphy: is there a pathologic significance in breast cancer? J Nucl Med. 2003;44:1232-1237.
33. Lerman H, Lievshitz G, Zak O, Metser U, Schneebaum S, Even-Sapir E. Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med. 2007;48:201-206. (Pubitemid 47555344)
34. van der Ploeg IM, Nieweg OE, Kroon BB, et al. The yield of SPECT/CT for anatomical lymphatic mapping in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:903-909.
35. Ibusuki M, Yamamoto Y, Kawasoe T, et al. Potential advantage of preoperative three-dimensional mapping of sentinel nodes in breast cancer by a hybrid single photon emission CT (SPECT)/CT system. Surg Oncol. 2010;19:88-94.
36. Bourgeois P, Nogaret JM, Veys I, et al. Isotope labelling and axillary node harvesting strategies for breast cancer. Eur J Surg Oncol. 2008;34:615-619. (Pubitemid 351671969)
37. Giard S, Chauvet MP, Penel N, et al. Feasibility of sentinel lymph node biopsy in multiple unilateral synchronous breast cancer: results of a French prospective multi-institutional study (IGASSU 0502). Ann Oncol. 2010;21:1630-1635.
38. Chung A, Giuliano A. Axillary staging in the neoadjuvant setting. Ann Surg Oncol. 2010;17:2401-2410.
39. Menard JP, Extra JM, Jacquemier J, et al. Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy. Eur J Surg Oncol. 2009;35:916-920.
40. Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27:726-732.
41. Baruah BP, Goyal A, Young P, Douglas-Jones AG, Mansel RE. Axillary node staging by ultrasonography and fine-needle aspiration cytology in patients with breast cancer. Br J Surg. 2010;97:680-683.
42. Heusner TA, Kuemmel S, Hahn S, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543-1550.
43. 18F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008;71:695-704.
44. 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging. November 12, 2010 [Epub ahead of print].
45. Julian TB, Blumencranz P, Deck K, et al. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol. 2008;26:3338-3345.
46. Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management-a systematic review. J Clin Oncol. 2008;26:4981-4989.
47. Estourgie SH, Tanis PJ, Nieweg OE, Valdés Olmos RA, Rutgers EJ, Kroon BB. Should the hunt for internal mammary chain sentinel nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol. 2003;10:935-941. (Pubitemid 40486860)
48. Paredes P, Vidal-Sicart S, Zanón G, et al. Clinical relevance of sentinel lymph nodes in the internal mammary chain in breast cancer patients. Eur J Nucl Med Mol Imaging. 2005;32:1283-1287. (Pubitemid 41598719)
49. Leidenius MH, Krogerus LA, Toivonen TS, Leppänen EA, von Smitten KA. The clinical value of parasternal sentinel node biopsy in breast cancer. Ann Surg Oncol. 2006;13:321-326. (Pubitemid 43255914)
50. Madsen E, Gobardhan P, Bongers V, et al. The impact on post-surgical treatment of sentinel lymph node biopsy of internal mammary lymph nodes in patients with breast cancer. Ann Surg Oncol. 2007;14:1486-1492. (Pubitemid 46536812)
51. Heuts EM, van der Ent FW, Hulsewé KW, von Meyenfeldt MF, Voogd AC. Results of tailored treatment for breast cancer patients with internal mammary lymph node metastases. Breast. 2009;18:254-258.
52. Bourre JC, Payan R, Collomb D, et al. Can the sentinel lymph node technique affect decisions to offer internal mammary chain irradiation? Eur J Nucl Med Mol Imaging. 2009;36:758-764.
53. van der Heiden-van der Loo M, Bezemer PD, Hennipman A, et al. Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol. 2006;32:710-714. (Pubitemid 44276004)
54. Hansen NM, Grube B, Ye X, et al. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol. 2009;27:4679-4684.
55. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for nodepositive breast cancer. J Clin Oncol. 2009;27:2946-2953.
56. Cox CE, Kiluk JV, Riker AI, et al. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg. 2008;206:261-268.
57. Tan LK, Giri D, Hummer AJ, et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol. 2008;26:1803-1809.
58. de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;361:653-663.
59. Coutant C, Olivier C, Lambaudie E, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27:2800-2808.
60. Houvenaeghel G, Nos C, Giard S, et al. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol. 2009;35:690-695.
61. Rodriguez Fernandez J, Martella S, Trifirò G, et al. Sentinel node biopsy in patients with previous breast aesthetic surgery. Ann Surg Oncol. 2009;16:989-992.
62. Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging. 2010;37:78-83.
63. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102:170-178.
64. Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. Ann Surg. 2008;247:315-319. (Pubitemid 351156776)
65. Tunon-de-Lara C, Giard S, Buttarelli M, et al. Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy. Breast J. 2008;14:135-140. (Pubitemid 351341834)
66. Boneti C, Korourian S, Diaz Z, et al. Scientific Impact Award: axillary reverse mapping (ARM) to identify and protect lymphatics draining the arm during axillary lymphadenectomy. Am J Surg. 2009;198:482-487.
67. Bedrosian I, Babiera GV, Mittendorf EA, et al. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010;116:2543-2548.
68. Mariscal Martínez A, Solà M, de Tudela AP, et al. Radioguided localization of nonpalpable breast cancer lesions: randomized comparison with wire localization in patients undergoing conservative surgery and sentinel node biopsy. AJR. 2009;193:1001-1009.
69. van Rijk MC, Tanis PJ, Nieweg OE, et al. Sentinel node biopsy and concomitant probe-guided tumor excision of nonpalpable breast cancer. Ann Surg Oncol. 2007;14:627-632. (Pubitemid 46175308)
70. Vermeeren L, Valdés Olmos RA, Klop WM, Balm AJ, van den Brekel MW. A portable gamma-camera for intraoperative detection of sentinel nodes in the head and neck region. J Nucl Med. 2010;51:700-703.
71. Canavese G, Catturich A, Vecchio C, et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol. 2009;20:1001-1007.